Recent bribery and corruption enforcement efforts by the US Department of Justice (DOJ) and US Securities and Exchange Commission (SEC), combined with new legislative and policy initiatives, including last December’s passage...more
Please join McDermott for our highly anticipated Life Sciences Dealmaking Symposium! Now in its 12th year, the Symposium offers a unique platform for education, insight sharing, purposeful networking and strategic...more
10/23/2023
/ Acquisitions ,
Artificial Intelligence ,
Asset Valuations ,
Capital Markets ,
Capital Raising ,
Carve Out Provisions ,
Collaboration ,
Cross-Border Transactions ,
Events ,
Health Care Providers ,
Health Technology ,
Initial Public Offering (IPO) ,
Investors ,
IP License ,
IP Portfolio ,
Life Sciences ,
Mergers ,
Pharmaceutical Industry ,
Private Equity Firms ,
Publicly-Traded Companies ,
Special Purpose Acquisition Companies (SPACs)